Pharmacy and Therapeutics (P&T) Committee
The Department of Human Services (Department) appointed the P&T Committee to act in an advisory capacity to the Department and the Office of Medical Assistance Programs (OMAP) and provide an unbiased clinical perspective on the Department's Statewide Preferred Drug List (PDL). Recommendations from the committee must be reviewed and approved by the Secretary of the Department of Human Services.
Change Healthcare provides clinical and financial analysis support to the P&T Committee.
P&T Committee Meeting Information
Upcoming Meetings
Dates:
Tuesday, September 14, 2021, 12:00pm-4:00pm, and Wednesday, September 15, 2021, 9:00am-4:00pm
Location:
The September P&T Committee meetings will be held virtually. Registraton to join the webinar will be posted on this website at least 14 days prior to the meetings.
Due to the virtual format of the meetings, only written public testimony will be accepted and must be submitted at least 14 days prior to the meeting. The written testimony will be distributed to all P&T Committee members prior to the meetings. Testimony should be emailed to RA-PharmForms@pa.gov.
The agenda will be posted prior to the meeting.
Past Pharmacy and Therapeutics Committee Meetings
Review the Pharmacy and Therapeutics Committee By-Laws
Committee Information
Composition and responsibilities of the committee:
- Comprised of department medical directors, external physicians, pharmacists, consumer advocates, and specialists as needed for drug class reviews.
- Recommend a clinically-based PDL with an emphasis on effectiveness, safety, and outcomes.
- Recommend prior authorization guidelines for non-preferred drugs as well as certain preferred drugs using current community standards for prescribing.
- Recommend Prospective and Retrospective Drug Utilization Review Program Review and Development.
|
Name |
Specialty |
Independent* |
Department** |
MCO |
| Ivonne Acrich, MD | Ad Hoc Child/Adolescent Psychiatrist
| | X | |
| Dale Adair, MD, FAPA | Office of Mental Health & Substance Abuse Services Medical Director | | X | |
| Christopher Antypas, PharmD | Community Pharmacist | X | | |
| Lawrence Appel, MD, SFHM | Medical Director, Office of Long Term Living
| | X
| |
| Cheston Berlin, Jr., MD | Pediatrician | X
| | |
| Tony Byler, MD | PerformCare Psychiatrist | | | X |
Terri Cathers, PharmD,
Chair (tie-breaker vote only) | OMAP Pharmacy Director
|
| X | |
| Sharon Connor, PharmD | Academic Pharmacist | X | | |
| Oluwatoyin Fadeyibi, PharmD, MPH | Community Behavioral Health Pharmacist | | | X |
| Andrea Fox, MD | Internist | X | | |
| Donald Gerhart, RPh | Community Pharmacist | X | | |
| James Hancovsky, RPh, MBA | United Health Care Pharmacy Director | | | X |
| David Haverstick, MD | Family Practitioner | X | | |
| Rosemary Keffer, MD | Ad Hoc Adult Psychiatrist | X | | |
| David Kelley, MD | OMAP Chief Medical Officer, Office of Medical Assistance Programs | | X | |
| Peter Kreckel, RPh | Community Pharmacist | X | | |
| Renee Licwinko, RPh | Gateway Health Plan Pharmacist | | | X |
| Hannah Livengood, PharmD | Health Partners of Philadelphia Pharmacist | | | X |
| Andrew Maiorini, PharmD | Keystone/AmeriHealth Perform Rx Clinical Pharmacist | | | X |
| Meghan McNelly, PharmD | PA Health & Wellness Pharmacist | | | X |
| Michele Musheno, RPh, MS | Academic/Hospital Pharmacist | X | | |
| Geoffrey Neimark, MD | Community Care Behavioral Health Psychiatrist | | | X |
| Natalie Nkurunziza, PharmD | Aetna Better Health Pharmacist | | | X |
| Louis Parrott Jr., MD, PhD | Magellan Healthcare Psychiatrist | | | X |
| Ian Paul, MD | Pediatrician | X | | |
| Adam Raphael Rom, MD | Family Practitioner | X | | |
| Amy Saracino, MD | Ad Hoc Adult Psychiatrist | | X | |
| Kevin Szczecina, RPh | Geisinger Health Plan Pharmacist | | | X |
| Mahmood Usman, MD | Beacon Health Options Psychiatrist | | | X |
| Andreas Wali, MD | Cardiologist | X | | |
| Lloyd Wertz | Consumer/Family Advocate | X | | |
| Lauren Zandier, PharmD | UPMC For You Pharmacist | | | X |
| Vacant | Consumer Representative | X | | |
* - Independent Members are not employed by the Department
** - Department Members are employed by the Department on a full or part-time basis
Effective October 22, 2020 / Last modified October 2020